KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Q3 2025 value amounting to $12.5 million.

  • Acadia Pharmaceuticals' Gains from Investment Securities changed N/A to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $146.5 million for FY2024, which is 78123.87% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Gains from Investment Securities is $12.5 million.
  • Acadia Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $16.6 million during Q4 2023, with a 5-year trough of $12.5 million in Q3 2025.
  • Its 4-year average for Gains from Investment Securities is $15.1 million, with a median of $15.7 million in 2021.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Gains from Investment Securities surged by 3445.76% in 2021, and later surged by 175.38% in 2023.
  • Over the past 4 years, Acadia Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $15.1 million in 2021, then increased by 8.31% to $16.3 million in 2022, then increased by 1.75% to $16.6 million in 2023, then dropped by 24.73% to $12.5 million in 2025.
  • Its Gains from Investment Securities stands at $12.5 million for Q3 2025, versus $16.6 million for Q4 2023 and $16.3 million for Q4 2022.